Table 2

Distribution of MPL mutations according to diagnosis in the Pavia and Florence merged cohorts

DiagnosisW515L*W515KW515AW515R†W515SS505N
Essential thrombocythemia 22 (55%) 7 (17.5%) 6 (15%) 2 (5%) 2 (5%) 1 (2.5%) 
Primary myelofibrosis 13 (92.9%) 1 (7.1%) 0 0 0 0 
Post-essential thrombocythemia myelofibrosis 4 (50%) 3 (37.5%) 1 (12.5%) 0 0 0 
DiagnosisW515L*W515KW515AW515R†W515SS505N
Essential thrombocythemia 22 (55%) 7 (17.5%) 6 (15%) 2 (5%) 2 (5%) 1 (2.5%) 
Primary myelofibrosis 13 (92.9%) 1 (7.1%) 0 0 0 0 
Post-essential thrombocythemia myelofibrosis 4 (50%) 3 (37.5%) 1 (12.5%) 0 0 0 
*

Two patients had another concomitant MPL mutation (S505C, V501A).

†

Two patients had another concomitant MPL mutation (V501A, Q516E).

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal